WCN 2021 and Multiple Sclerosis And Related Disorders View overview page

0:46
Similarities between the gut microbiome in Parkinson’s disease & MS
Paul Wilmes • 5 Oct 2021
5:10
PREVENT study: eculizumab in AQP4-IgG-positive NMOSD
Kazuo Fujihara • 4 Oct 2021
1:21
Novel treatment strategies for NMOSD
Kazuo Fujihara • 4 Oct 2021
2:24
Symptomatic treatment of NMOSD
Kazuo Fujihara • 4 Oct 2021
5:44
Diagnostic criteria and treatment updates for NMOSD
Kazuo Fujihara • 4 Oct 2021
3:14
Limitations of the current multiple sclerosis classification
Mar Tintoré • 4 Oct 2021
7:33
Comparing exit strategies in natalizumab-responders at high risk for PML
Emanuele D'Amico • 30 Sep 2021
1:50
Relapse-independent progression in multiple sclerosis
Mar Tintoré • 4 Oct 2021
2:11
Incorporating new measures to detect silent progression in multiple sclerosis
Mar Tintoré • 4 Oct 2021
4:03
Key areas of research in multiple sclerosis
Mar Tintoré • 4 Oct 2021
2:31
Learnings from laquinimod in MS
Giancarlo Comi • 28 Sep 2021
4:11
The story of laquinimod in multiple sclerosis
Giancarlo Comi • 28 Sep 2021
1:52
Understanding the mechanisms of communication between CNS cell subtypes
Francisco Quintana • 20 Sep 2021
2:23
Developing modulators for pathogenic astrocyte subsets in MS
Francisco Quintana • 20 Sep 2021
3:11
Mechanisms used by astrocytes to control CNS pathology
Francisco Quintana • 20 Sep 2021
1:18
Varying functions of astrocyte subsets in MS pathology
Francisco Quintana • 20 Sep 2021
The content of VJNeurology is intended for healthcare professionals